LEADER 05271nam 2201585z- 450 001 9911053032003321 005 20230911 035 $a(CKB)5690000000228617 035 $a(oapen)doab113964 035 $a(EXLCZ)995690000000228617 100 $a20230920c2023uuuu -u- - 101 0 $aeng 135 $aurmn|---annan 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 00$aUpdates on Molecular Targeted Therapies for CNS Tumors 210 $cMDPI - Multidisciplinary Digital Publishing Institute$d2023 215 $a1 online resource (368 p.) 311 08$a3-0365-8529-X 330 $aThe challenges in identifying effective therapies for CNS tumors continue to be daunting. Potentially effective targeted therapies must be able to penetrate the blood-brain barrier to reach the tumor and, in sufficient concentrations, to result in meaningful treatment responses. Moreover, molecular targets must be key drivers in the growth and progression of CNS tumors. Numerous potentially efficacious therapies have failed in randomized clinical trials due to other factors, including subclonal genetic intratumoral heterogeneity (particularly within malignant gliomas), epigenetic heterogeneity, and failure to target important factors involved in the tumor microenvironment. Developing effective targeted therapies requires a thorough fundamental understanding of the genetic and epigenetic factors driving tumor progression, the interactions between CNS tumor cells and the tumor microenvironment, and the key mechanisms of tumor treatment resistance. In this Special Issue, experts in the field of CNS tumors will highlight the most promising molecular targets in the development of treatments for patients with CNS tumors. 606 $aMedicine and Nursing$2bicssc 606 $aOncology$2bicssc 610 $aA172 610 $aA2AAR antagonist 610 $aadenosine 610 $aadenosine receptors 610 $aantigen processing and presentation 610 $aantioxidant 610 $aapoptosis 610 $aATRX 610 $abevacizumab 610 $abiomarker 610 $ablood-brain barrier 610 $abrain metastasis 610 $abrain tumor 610 $acancer metabolism 610 $acell cycle arrest 610 $acentral nervous system 610 $achemotherapy 610 $aCNS disease 610 $aCNS lymphoma 610 $aCpG island 610 $adiffuse midline gliomas 610 $aDNMT 610 $aEGFR 610 $aependymoma 610 $aEPHB2 610 $aepidermal growth factor receptor 610 $aERK/MAPK pathway 610 $aFGFR3 610 $aG-CIMP 610 $aGBM 610 $agermline mutation 610 $aglioblastoma 610 $aglioblastoma molecular classification 610 $aglioma 610 $aGroup A 610 $aGroup B 610 $aH3K27M 610 $ahistone acetylation 610 $aIDH-mutant glioma 610 $aimmune evasion 610 $aimmune score 610 $aimmunotherapy 610 $aintraparenchymal metastases 610 $aintrathecal 610 $aisotope labeling 610 $aKIF11 610 $aleptomeningeal 610 $alow grade glioma 610 $alow-grade glioma 610 $aLPS 610 $alung cancer 610 $alung carcinoma 610 $alung malignancy 610 $amass spectrometry 610 $ameningitis 610 $aMET 610 $ametastatic disease 610 $aMetformin 610 $amethotrexate 610 $amethylation 610 $amethylomics 610 $amethyltransferases 610 $aMGMT 610 $amolecular targets 610 $amolecular therapy 610 $amonoclonal antibodies 610 $aMYCN 610 $amyxopapillary 610 $an/a 610 $aneoantigen 610 $aneoplastic 610 $aneurofibromatosis 610 $aNF1 610 $anovel therapeutics 610 $anovel therapies 610 $apatient avatars 610 $aPCNSL 610 $aPDGFRA 610 $apediatric brain tumor 610 $aPFA 610 $aPFB 610 $aPI3K/PTEN pathway 610 $aplexiform neurofibroma 610 $apotential therapy development 610 $apreclinical models 610 $aprogression 610 $aprogression-free survival 610 $aradiotherapy 610 $areceptor tyrosine kinase 610 $aRELA 610 $astereotactic radiosurgery 610 $asubependymoma 610 $aT cells 610 $aT lymphocytes 610 $atargeted therapy 610 $atemozolomide 610 $atumor microenvironment 610 $atumor mutation burden 610 $atumor suppressor 610 $atyrosine kinase inhibitors 610 $aU87MG 610 $avestibular schwannoma 610 $aWarburg effect 610 $awhole-brain radiation therapy 610 $aYAP1 610 $aZFTA 615 7$aMedicine and Nursing 615 7$aOncology 906 $aBOOK 912 $a9911053032003321 996 $aUpdates on Molecular Targeted Therapies for CNS Tumors$94526180 997 $aUNINA